LYRA vs ARWR vs PRAX vs REGN

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 2x trailing P/E (15. 5x forward), making it the more compelling value choice. Analysts rate Arrowhead Pharmaceuticals, Inc. (ARWR) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Regeneron Pharmaceuticals, Inc.

(REGN) delivered a total return of +43. 2%, compared to -99. 9% for Lyra Therapeutics, Inc. (LYRA). Over 10 years, the gap is even starker: ARWR returned +1162% versus LYRA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lyra Therapeutics, Inc.

(LYRA) is the lower-risk stock at 0. 70β versus Arrowhead Pharmaceuticals, Inc. 's 1. 74β — meaning ARWR is approximately 148% more volatile than LYRA relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 3% for Lyra Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Arrowhead Pharmaceuticals, Inc. grew EPS 99. 8% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, LYRA leads at 75. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -60. 9% for Lyra Therapeutics, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -62. 8% for LYRA. At the gross margin level — before operating expenses — LYRA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PRAX: 66.

3% to $548. 80.

In this comparison, REGN (0.

5% yield) pays a dividend. LYRA, ARWR, PRAX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77)). Both have compounded well over 10 years (REGN: +91. 6%, PRAX: -20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LYRA is a small-cap quality compounder stock; ARWR is a mid-cap high-growth stock; PRAX is a small-cap quality compounder stock; REGN is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.